

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

Celltrion, Inc.  
Petitioner,

v.

Genentech, Inc.  
Patent Owner

Patent No. 6,407,213

---

*Inter Partes* Review No. IPR2017-01373

---

**PETITIONER'S SIXTH UPDATED MANDATORY NOTICES**

Celltrion, Inc. hereby updates its Mandatory Notices pursuant to 37 C.F.R. § 42.8 to update related matters.

Patent No. 6,407,213 (“the ’213 patent”) is related to the following patents: U.S. Pat. Nos. 6,639,055, 6,800,738, and 6,719,971 (all expired for maintenance fee non-payment), and U.S. Pat. No. 8,075,890.

Petitioner additionally challenged claims of the ’213 patent in IPR2017-01374, which was instituted. Pfizer Inc. challenged the ’213 patent in IPR2017-01488 and IPR2017-01489, which were both instituted. Boehringer Ingelheim Pharmaceuticals, Inc. challenged the ’213 patent in IPR2017-02031 and IPR2017-02032, which were both instituted. Samsung Bioepis Co., Ltd. challenged the ’213 patent in IPR2017-02139 and IPR2017-02140. Those proceedings were instituted and joined with IPR2017-01488 and IPR2017-01489, respectively. Mylan Pharmaceuticals Inc. challenged the ’213 patent in IPR2016-01693 and IPR2016-01694, which were both terminated.

The ’213 patent is at issue in the following litigations: *Amgen Inc. v. Genentech, Inc. et al*, No. 17-cv-7349 (C.D. Cal.) (now dismissed); *Genentech, Inc. et al v. Amgen Inc.*, No. 17-cv-1407 (D. Del.); *Genentech, Inc. et al v. Amgen Inc.*, No. 17-cv-1471 (D. Del.); *Genentech, Inc. v. Pfizer, Inc.*, No. 17-cv-1672 (D. Del.); *Celltrion, Inc. v. Genentech, Inc.*, No. 18-cv-274 (N.D. Cal.) *appeal docketed*, No. 18-2160 (Fed. Cir. July 16, 2018); *Genentech, Inc. v. Celltrion,*

*Inc.*, No. 18-cv-095 (D. Del.); *Genentech, Inc. et al. v. Amgen Inc.*, No. 18-cv-924 (D. Del.); *Genentech, Inc. et al. v. Celltrion, Inc. et al.*, No. 18-cv-1025 (D. Del.); and *Genentech, Inc. et al. v. Samsung Bioepis Co., Ltd.*, No. 18-cv-1363 (D. Del.).

Dated: October 1, 2018

By: */Cynthia Lambert Hardman/*  
Cynthia Lambert Hardman (Reg. No. 53,179)  
Elizabeth J. Holland (Reg. No. 47,657)  
Robert V. Cerwinski (admitted *pro hac vice*)  
Linnea P. Cipriano (Reg. No. 67,729)  
GOODWIN PROCTER LLP  
The New York Times Building  
620 Eighth Avenue  
New York, NY 10018  
(212) 813-8800 (telephone)  
(212) 355-3333 (facsimile)

Sarah J. Fischer (Reg. No. 74,104)  
GOODWIN PROCTER LLP  
100 Northern Avenue  
Boston, MA, 02210  
(617) 570-3908 (telephone)  
(617) 801-8991 (facsimile)

*Counsel for Petitioner*

## CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 1<sup>st</sup> day of October, 2018, I caused a copy of this PETITIONER'S SIXTH UPDATED MANDATORY NOTICES to be served by email on the lead and back up counsel for Patent Owners at:

David Cavanaugh (David.Cavanaugh@wilmerhale.com)

Lauren V. Blakely (lauren.blakely@wilmerhale.com)

Robert Gunther (Robert.Gunther@wilmerhale.com)

Adam Brausa (abrausa@durietangri.com)

Daralyn Durie (ddurie@durietangri.com)

Andrew Danford (Andrew.Danford@wilmerhale.com)

Lisa Pirozzolo (Lisa.Pirozzolo@wilmerhale.com)

Kevin Prussia (Kevin.Prussia@wilmerhale.com)

/Cynthia Lambert Hardman/

Cynthia Lambert Hardman (Reg. No. 53,179)

GOODWIN PROCTER LLP  
The New York Times Building  
620 Eighth Avenue  
New York, NY 10018  
(212) 813-8800 (telephone)  
(212) 355-3333 (facsimile)